Fragment-based inhibitor design for SARS-CoV2 main protease

Area of Science:

• Medicinal Chemistry
• Computational Biology
• Virology

Background:

• Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes COVID-19, a global pandemic with significant mortality.
• Targeting the SARS-CoV-2 main protease is a key strategy for developing antiviral therapies.
• The protease is essential for viral replication, cleaving polyproteins into functional units.

Purpose of the Study:

• To identify novel hit molecule inhibitors for the SARS-CoV-2 main protease.
• To utilize fragment-based drug discovery (FBDD) approach.
• To leverage the crystal structure of a known chromene-based inhibitor (PDB_ID: 6M2N).

Main Methods:

• Fragment-based drug discovery (FBDD) was employed.
• Molecular docking and molecular dynamics simulations were used for validation.
• Binding free energies, normal mode analysis, mechanical stiffness, and principal component analysis assessed complex stability.

Main Results:

• Novel hit molecules targeting the SARS-CoV-2 main protease were identified.
• Computational validation confirmed the stability and binding of designed inhibitors.
• Detailed analyses provided insights into the molecular interactions and stability of the complexes.

Conclusions:

• The study successfully identified potential inhibitors for SARS-CoV-2 main protease using FBDD.
• Computational simulations validated the efficacy and stability of these drug candidates.
• These findings contribute to the development of new therapeutic strategies against COVID-19.